Insights Into Cytokine-Receptor Interactions from Cytokine Engineering.
Stanford, United States. In Annu Rev Immunol, 10 Jan 2015
Here we review the theory and practice of cytokine engineering and rationalize the mechanisms of several engineered cytokines in the context of structure.Wediscuss specific examples of how structure-based cytokine engineering has opened new opportunities for cytokines as drugs, with a focus on the immunotherapeutic cytokines interferon, interleukin-2, and interleukin-4.
Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer.
Buraydah, Saudi Arabia. In World J Clin Oncol, 10 Jan 2015
Th1 and Th2 cytokines [interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12 (p70), tumor necrosis factor (TNF)-α, TNF-β, and interferon-γ] analysis revealed no significant difference between patients with NSCLC and non-cancer controls.
Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Ann Arbor, United States. In J Clin Oncol, 20 Dec 2014
PATIENTS AND METHODS: S0008 (S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage IIIA-N2a through IIIC-N3), randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-α-2b) and granulocyte colony-stimulating factor given every 21 days for three cycles.
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
London, United Kingdom. In N Engl J Med, 09 Nov 2014
BACKGROUND: In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients.
Salivary markers of inflammation in response to acute stress.
Penn Hills, United States. In Brain Behav Immun, Oct 2014
Results from each study are reviewed by analyte (IL-1β, TNF-α, IL-6, IL-2, IL-4, IL-10, IL-12, CRP) and stress type (social-cognitive and exercise-physical), after which methodological issues and limitations are addressed.
Immunosuppression in lung transplantation.
Columbia, United States. In J Thorac Dis, Aug 2014
Roughly 50% of lung transplant centers also utilize induction therapy, with polyclonal antibody preparations [equine or rabbit anti-thymocyte globulin (ATG)], interleukin 2 receptor antagonists (IL2RAs) (daclizumab or basiliximab), or alemtuzumab.
Advances in the Systemic Treatment of Metastatic Melanoma.
More papers using
In Oncology (williston Park), Jun 2013
UNLABELLED: Prior to 2011, the only commercially available agents commonly used to treat metastatic melanoma-including dacarbazine, temozolomide (Temodar), fotemustine, carboplatin, paclitaxel, and interleukin-2-demonstrated limited efficacy, and no study involving these agents had shown an improvement in overall survival.
Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.
In PLoS ONE, 1999
... (BioWhittaker, Verviers, Belgium) supplemented with 10% fetal calf serum (PAA Laboratories, Vienna, Austria), 10 U/ml IL-2 (National Institutes of Health, AIDS Repository), 2 mM L-glutamine (Invitrogen Life Technologies, Paisley, Scotland), and 1% ...